News &amp; Updates

Treatment with clevidipine in patients undergoing cardiac surgery leads to better perioperative blood pressure (BP) control relative to nicardipine, with a slight rise in cost and no significant difference in safety outcomes, a study has found.

Clevidipine trumps nicardipine for BP control in patients undergoing cardiac surgery

GLP1RA added to antidiabetic drugs prevents MACE, HF hospitalization

Adding glucagon-like peptide-1 receptor agonists (GLP1RA) onto metformin, sulfonylurea, or insulin treatment alone or in combination appears to reduce the incidence of major adverse cardiac events (MACE) and heart failure (HF) hospitalization relative to treatment with dipeptidyl peptidase-4 inhibitors (DPP4i), suggests a study.

GLP1RA added to antidiabetic drugs prevents MACE, HF hospitalization

Amiodarone plus apixaban/rivaroxaban ups bleeding-related hospitalizations in older AF patients

Use of amiodarone in older patients with atrial fibrillation (AF) who are being treated with apixaban or rivaroxaban results in a higher risk of bleeding-related hospitalizations compared with the use of flecainide or sotalol, reports a study.

Amiodarone plus apixaban/rivaroxaban ups bleeding-related hospitalizations in older AF patients

Serum ADMA levels linked to circadian BP variability in glaucoma

Serum levels of asymmetric dimethylarginine (ADMA) seem to play a major role in the disturbance of circadian blood pressure (BP) variability in patients with glaucoma, suggests a recent study.

Serum ADMA levels linked to circadian BP variability in glaucoma

27 May 2023

Long-term ACS outcomes similar between TiNO-coated and everolimus-eluting stents

Neither titanium-nitride-oxide (TiNO)–coated stents nor third-generation everolimus-eluting stents (EES) are necessarily better than the other in the treatment of patients with acute coronary syndromes (ACS), with a study showing no significant difference in long-term outcomes following placement of TiNO-coated stents or EES.

Long-term ACS outcomes similar between TiNO-coated and everolimus-eluting stents

27 May 2023

HCT treatment tied to lower cancer risk, except skin cancer

26 May 2023

Treatment with hydrochlorothiazide (HCT) contributes to a lower all-cancer risk and a slightly higher skin cancer risk compared with alternative diuretics, reports a study involving a German population.

HCT treatment tied to lower cancer risk, except skin cancer

26 May 2023

Pulsed field ablation benefits most patients with AF treated in usual clinical care

Catheter ablation using pulsed field energy leads to freedom from atrial arrhythmia in many patients with atrial fibrillation (AF), according to data from MANIFEST-PF*.

Pulsed field ablation benefits most patients with AF treated in usual clinical care

CHIP predicts adverse outcomes in atherosclerotic CVD

Clonal haematopoiesis of indeterminate potential (CHIP) appears to independently contribute to adverse outcomes in individuals with established atherosclerotic cardiovascular disease (ASCVD), reveals a recent study, noting the high risks in TET2 and SF3B1/SRSF2/U2AF1 CHIP.

CHIP predicts adverse outcomes in atherosclerotic CVD

23 May 2023

Eplontersen promising for hereditary ATTRv-PN

23 May 2023 by

Eplontersen, a ligand-conjugated antisense (LICA) investigational agent designed to reduce transthyretin (TTR) production or TTR protein, ably halts neuropathy progression and improves quality of life (QoL) in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) in the phase III NEURO-TTRansform trial.

Eplontersen promising for hereditary ATTRv-PN